Peptide comparison
They are not two versions of the same thing. Semaglutide mimics GLP-1, a gut hormone; cagrilintide mimics amylin, a pancreatic hormone. They act on different receptors that regulate food intake through complementary routes, which is why research has focused on combining them.
Compare mechanism, class, receptors and evidence. All compounds are offered with ≥99% purity verified by HPLC and a batch COA.
| Cagrilintide | Semaglutide | |
|---|---|---|
| Hormone it mimics | Amylin (pancreas) | GLP-1 (gut) |
| Receptors | Amylin and calcitonin receptors | GLP-1 receptor |
| Long-acting strategy | Lipidation (albumin binding) | Lipidation (C18 diacid, albumin binding) |
| Described actions | Satiety, gastric emptying, lower post-meal glucagon | Glucose-dependent insulin secretion, satiety, gastric emptying |
| Clinical development | In clinical research, mainly in combination | Complete; approved medicine |
| Relationship between them | Researched in combination with semaglutide | Basis of the combination |
Semaglutide is the reference GLP-1 agonist: it amplifies insulin when glucose is high, slows gastric emptying and acts on the brain's appetite centres. Its clinical development is complete. Cagrilintide is a long-acting amylin analogue; amylin is released together with insulin and acts in brainstem regions involved in satiety, as well as reducing glucagon after meals.
Because the two hormones regulate food intake through different mechanisms, their effects can add up. That is the logic of the large clinical programmes studying cagrilintide combined with semaglutide. That is why cagrilintide is best understood as a complement to the GLP-1 pathway rather than an alternative to it.
💡 Want the complete scientific foundations? See the Peptide guide or the Certification in Peptide Science.
No. It is an amylin analogue that acts on amylin and calcitonin receptors. Its pathway is different from and complementary to GLP-1.
Because GLP-1 and amylin regulate food intake through different mechanisms, so their effects can add up. The cagrilintide + semaglutide combination is being investigated in large-scale clinical programmes.
Semaglutide is approved as a medicine. Cagrilintide is still in clinical research. The material in this catalogue is for research use only.
Purity ≥99% verificada por HPLC and batch COA.
View full catalog →